Research Article
Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia
Table 2
Clinical and demographic characteristics of patients with positive serological markers for HBV and HCV.
| Code | Diagnosis | Origin | Age | Gender | Alcohol* | Type of simple | Serological marker | Serum | Liver tissue | HBsAg | Anti-HCV |
| UdeA-001 | Ci | Colombia | 68 | F | 4 | NA | Yes | Neg | Pos | UdeA-002 | Ci | Colombia | 59 | M | 4 | NA | Yes | Neg | Pos | UdeA-003 | Ci | Colombia | 68 | M | 4 | NA | Yes | Neg | Pos | UdeA-004 | Ci | Colombia | 47 | M | 4 | Yes | NA | Pos | Neg | UdeA-006 | HCC + Ci | Colombia | 48 | M | 4 | NA | Yes | Neg | Pos | UdeA-009 | Ci | Colombia | 69 | M | 1 | Yes | NA | Pos | Neg | UdeA-015 | HCC + Ci | Colombia | 68 | F | 9 | NA | Yes | Neg | Pos | UdeA-024 | Ci | El Salvador | 60 | M | 9 | NA | Yes | Pos | Neg | UdeA-054 | Ci | Venezuela | 47 | M | 3 | Yes | Yes | Pos | Neg | UdeA-056 | HCC + Ci | Colombia | 56 | F | 4 | Yes | NA | Pos | Neg | UdeA-058 | HCC + Ci | Colombia | 53 | M | 9 | Yes | NA | Pos | Neg | UdeA-061 | Ci | Colombia | 47 | F | 4 | Yes | NA | Pos | Neg | UdeA-065 | Ci | Colombia | 58 | F | 1 | NA | Yes | Neg | Pos | UdeA-069 | HCC | Colombia | 64 | F | 4 | NA | Yes | Neg | Pos | UdeA-070 | Ci | Colombia | 34 | M | 4 | NA | Yes | Neg | Pos | UdeA-072 | Ci | Israel | 49 | M | 3 | Yes | Yes | Pos | Neg | UdeA-077 | Ci | Colombia | 57 | M | 1 | Yes | NA | Pos | Neg | UdeA-083 | HCC + Ci | Colombia | 67 | F | 4 | Yes | Yes | Pos | Neg | UdeA-087 | Ci | Colombia | 48 | M | 2 | Yes | NA | Pos | Neg | UdeA-089 | HCC + Ci | Colombia | 47 | F | 4 | Yes | Yes | Pos | Neg | UdeA-099 | Ci | Colombia | 56 | M | 4 | Yes | NA | Pos | Neg | UdeA-101 | Ci | Colombia | 74 | F | 4 | Yes | NA | Pos | Neg | UdeA-124 | HCC + Ci | Colombia | 57 | M | 2 | Yes | NA | Pos | Neg |
|
|
ci: Cirrhosis, HCC: hepatocellular carcinoma, M: male, F: female, *Alcohol intake: for male/(female) 1: >80 g/day (40g/day); 2: 50–80 g/day (20–40 g/day); 3: <50 g/day (20 g/day) 4: no intake; 9: no data; Yes: available; NA: nonavailable; Yes: HBV/HCV-positive sample by molecular analysis; Pos: positive serological result;Neg: negative serological result.
|